[HTML][HTML] Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction
Primary nonalcoholic fatty liver disease (NAFLD) is bi-directionally associated with the
metabolic syndrome and its constitutive features (“factors”: impaired glucose disposal …
metabolic syndrome and its constitutive features (“factors”: impaired glucose disposal …
Bidirectional association between psoriasis and nonalcoholic fatty liver disease: real-world evidence from two longitudinal cohort studies
Background Association between nonalcoholic fatty liver disease (NAFLD) and future
psoriasis has not yet been confirmed, although the two diseases partially share a common …
psoriasis has not yet been confirmed, although the two diseases partially share a common …
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis
K Sangha, ST Chang, R Cheung, VS Deshpande - Hepatology, 2023 - journals.lww.com
Methods: A Markov model was developed from the US perspective. The base-case scenario
in this model included patients aged 50 years with a Fibrosis-4 score of≥ 2.67 and …
in this model included patients aged 50 years with a Fibrosis-4 score of≥ 2.67 and …
Mori fructus aqueous extracts attenuates liver injury by inhibiting ferroptosis via the Nrf2 pathway
Y Wei, C Gao, H Wang, Y Zhang, J Gu, X Zhang… - Journal of Animal …, 2023 - Springer
Background Liver fibrosis and hepatocellular carcinogenesis secondary to liver fibrosis are
serious liver diseases with no effective treatments. Mori fructus aqueous extracts (MFAEs) …
serious liver diseases with no effective treatments. Mori fructus aqueous extracts (MFAEs) …
Glycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis
Liver fibrosis is characterized by the activation of perivascular hepatic stellate cells (HSCs),
the release of fibrogenic nanosized extracellular vesicles (EVs), and increased HSC …
the release of fibrogenic nanosized extracellular vesicles (EVs), and increased HSC …
Co-treatments of gardeniae fructus and silymarin ameliorates excessive oxidative stress-driven liver fibrosis by regulation of hepatic Sirtuin1 activities using …
JA Lee, MR Shin, JW Choi, MJ Kim, HJ Park, SS Roh - Antioxidants, 2022 - mdpi.com
Gardeniae Fructus (GF, the dried ripe fruits of Gardenia jasminoides Ellis) has traditionally
been used to treat various diseases in East Asian countries, such as liver disease. Silymarin …
been used to treat various diseases in East Asian countries, such as liver disease. Silymarin …
Quality of life in adults with metabolic dysfunction-associated fatty liver disease
TI Hwang, AL Han - International Journal of Environmental Research and …, 2021 - mdpi.com
The aims of this study were as follows: to investigate the association between metabolic
dysfunction-associated fatty liver disease (MAFLD) and health-related quality of life …
dysfunction-associated fatty liver disease (MAFLD) and health-related quality of life …
Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis‐prevalence, clinical impact, economic implications and management strategies
Background The metabolically‐based liver disease, nonalcoholic fatty liver disease
(NAFLD), is the most common cause of chronic liver disease currently affecting 38% of the …
(NAFLD), is the most common cause of chronic liver disease currently affecting 38% of the …
Development of a predictive nomogram for in-hospital death risk in multimorbid patients with hepatocellular carcinoma undergoing Palliative Locoregional Therapy
R Yao, B Zheng, X Hu, B Ma, J Zheng, K Yao - Scientific Reports, 2024 - nature.com
Patients diagnosed with hepatocellular carcinoma (HCC) often present with multimorbidity,
significantly contributing to adverse outcomes, particularly in-hospital mortality. This study …
significantly contributing to adverse outcomes, particularly in-hospital mortality. This study …
[HTML][HTML] Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in …
The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH) presents many public health challenges, including a substantial …
steatohepatitis (NASH) presents many public health challenges, including a substantial …